Clinique Neuro-Outaouais — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
efgartigimod administrationThis study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.	Myasthénie	Phase 3	À vérifier	Canada	À vérifier
Repetitive Transcranial Magnetic StimulationStudy the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.	SEP	Non applicable	À vérifier	Canada	À vérifier
Repetitive Transcranial Magnetic StimulationStudy the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.	SEP	Non applicable	À vérifier	Canada	À vérifier
efgartigimod administrationThis study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.	Myasthénie	Phase 3	À vérifier	Canada	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
efgartigimod administration	Myasthénie	Phase 3	NCT06765161	Efgartigimod in IVIG Dependent Myasthenia Gravis Patients	RECRUITING
Repetitive Transcranial Magnetic Stimulation	SEP	Non applicable	NCT07159789	CeV — Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.